Ocean Biomedical, Inc. (OCEA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol OCEA
- Company Ocean Biomedical, Inc.
- Price $0
- Changes Percentage 100
- Change 0.001
- Day Low $0
- Day High $0
- Year High $0.76
- Year Low $0
- Market Cap $1,186,353
- Price Avg 50 EMA (D) $0
- Price Avg 200 EMA (D) $0.03
- Exchange NASDAQ
- Volume 7,780
- Average Volume 2,428,660
- Open $0
- Previous Close $0
- EPS -0.91
- PE 0.00
- Earnings Announcement 2025-04-08 12:30:00
- Shares Outstanding $232,365,000
Company brief: OCEAN BIOMEDICAL, INC. (OCEA )
- Healthcare
- Biotechnology
- Ms. Elizabeth Ng M.B.A.
- http://www.oceanbiomedical.com
- US
- N/A
- 11-08-2021
- US67644C1045
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.